Ana Carolina Alba

Ana Carolina Alba

Auto-generated profile, based on publicly available information

Ana Carolina Alba

Peter Munk Cardiac Centre, Ted Rogers Center for Heart Research, University Health Network, Toronto, Ontario, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2017 in JAMA
Verified
Journal Article
Closed access
PDF file
AAAna Carolina Alba
Ana Carolina Alba
TAThomas Agoritsas
Thomas Agoritsas
MWMichael Walsh
Michael Walsh
SHSteven Hanna
Steven Hanna
AIAlfonso Iorio
Alfonso Iorio
GGGordon Guyatt
Gordon Guyatt
Accurate information regarding prognosis is fundamental to optimal clinical care. The best approach to assess patient prognosis relies on prediction models that simultaneously consider a number of prognostic factors and provide an estimate of patients’ absolute risk of an event. Such prediction models should be characterized by adequately discriminating between patients who will have an event and those who will not and by adequate calibration ensuring accurate prediction of absolute risk. This Users’ Guide will help clinicians understand the available metrics for assessing discrimination, calibration, and the relative performance of different prediction models. This article complements existing Users’ Guides that address the development and validation of prediction models. Together, these guides will help clinicians to make optimal use of existing prediction models.

22 January 2014 in JAMA
Verified
Journal Article
Closed access
PDF file
XSXin Sun
Xin Sun
JIJohn P. A. Ioannidis
John P. A. Ioannidis
TAThomas Agoritsas
Thomas Agoritsas
AAAna C. Alba
Ana C. Alba
GGGordon Guyatt
Gordon Guyatt
Clinicians, when trying to apply trial results to patient care, need to individualize patient care and, potentially, manage patients based on results of subgroup analyses. Apparently compelling subgroup effects often prove spurious, and guidance is needed to differentiate credible from less credible subgroup claims. We therefore provide 5 criteria to use when assessing the validity of subgroup analyses: (1) Can chance explain the apparent subgroup effect; (2) Is the effect consistent across studies; (3) Was the subgroup hypothesis one of a small number of hypotheses developed a priori with direction specified; (4) Is there strong preexisting biological support; and (5) Is the evidence supporting the effect based on within- or between-study comparisons. The first 4 criteria are applicable to individual studies or systematic reviews, the last only to systematic reviews of multiple studies. These criteria will help clinicians deciding whether to use subgroup analyses to guide their patient care.

1 July 2013 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
RMReem A. Mustafa
Reem A. Mustafa
NSNancy Santesso
Nancy Santesso
JBJan Brozek
Jan Brozek
EAElie A. Akl
Elie A. Akl
SWStephen D. Walter
Stephen D. Walter
HSHolger J. Schünemann
Holger J. Schünemann

1 September 2013 in Circulation: Heart Failure
Verified
Journal Article
Closed access
AAAna C. Alba
Ana C. Alba
TAThomas Agoritsas
Thomas Agoritsas
MJMilosz Jankowski
Milosz Jankowski
DCDelphine Courvoisier
Delphine Courvoisier
SWStephen D. Walter
Stephen D. Walter
HRHeather J. Ross
Heather J. Ross
Background—: Optimal management of heart failure requires accurate assessment of prognosis. Many prognostic models are available. Our objective was to identify studies that evaluate the use of risk prediction models for mortality in ambulatory patients with heart failure and describe their performance and clinical applicability. Methods and Results—: We searched for studies in Medline, Embase, and CINAHL in May 2012. Two reviewers selected citations including patients with heart failure and reporting on model performance in derivation or validation cohorts. We abstracted data related to population, outcomes, study quality, model discrimination, and calibration. Of the 9952 studies reviewed, we included 34 studies testing 20 models. Only 5 models were validated in independent cohorts: the Heart Failure Survival Score, the Seattle Heart Failure Model, the PACE (incorporating peripheral vascular disease, age, creatinine, and ejection fraction) risk score, a model by Frankenstein et al, and the SHOCKED predictors. The Heart Failure Survival Score was validated in 8 cohorts (2240 patients), showing poor-to-modest discrimination ( c -statistic, 0.56–0.79), being lower in more recent cohorts. The Seattle Heart Failure Model was validated in 14 cohorts (16 057 patients), describing poor-to-acceptable discrimination (0.63–0.81), remaining relatively stable over time. Both models reported adequate calibration, although overestimating survival in specific populations. The other 3 models were validated in a cohort each, reporting poor-to-modest discrimination (0.66–0.74). Among the remaining 15 models, 6 were validated by bootstrapping ( c -statistic, 0.74–0.85); the rest were not validated. Conclusions—: Externally validated heart failure models showed inconsistent performance. The Heart Failure Survival Score and Seattle Heart Failure Model demonstrated modest discrimination and questionable calibration. A new model derived from contemporary patient cohorts may be required for improved prognostic performance.

1 October 2020 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
CFClaudia Frankfurter
Claudia Frankfurter
MMMicaela Molinero
Micaela Molinero
JVJulie K.K. Vishram-Nielsen
Julie K.K. Vishram-Nielsen
FFFarid Foroutan
Farid Foroutan
SMSusanna Mak
Susanna Mak
AAAna Carolina Alba
Ana Carolina Alba
Background: Right ventricular failure (RVF) is a cause of major morbidity and mortality after left ventricular assist device (LVAD) implantation. It is, therefore, integral to identify patients who may benefit from biventricular support early post-LVAD implantation. Our objective was to explore the performance of risk prediction models for RVF in adult patients undergoing LVAD implantation. Methods: A systematic search was performed on Medline, Embase, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews from inception until August 2019 for all relevant studies. Performance was assessed by discrimination (via C statistic) and calibration if reported. Study quality was assessed using the Prediction Model Risk of Bias Assessment Tool criteria. Results: After reviewing 3878 citations, 25 studies were included, featuring 20 distinctly derived models. Five models were derived from large multicenter cohorts: the European Registry for Patients With Mechanical Circulatory Support, Interagency Registry for Mechanically Assisted Circulatory Support, Kormos, Pittsburgh Bayesian, and Mechanical Circulatory Support Research Network RVF models. Seventeen studies (68%) were conducted in cohorts implanted with continuous-flow LVADs exclusively. The definition of RVF as an outcome was heterogenous among models. Seven derived models (28%) were validated in at least 2 cohorts, reporting limited discrimination (C-statistic range, 0.53–0.65). Calibration was reported in only 3 studies and was variable. Conclusions: Existing RVF prediction models exhibit heterogeneous derivation and validation methodologies, varying definitions of RVF, and are mostly derived from single centers. Validation studies of these prediction models demonstrate poor-to-modest discrimination. Newer models are derived in cohorts implanted with continuous-flow LVADs exclusively and exhibit modest discrimination. Derivation of enhanced discriminatory models and their validations in multicenter cohorts is needed.

1 August 2009 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
AAAna C. Alba
Ana C. Alba
VRVivek Rao
Vivek Rao
JIJoan Ivanov
Joan Ivanov
HRHeather J. Ross
Heather J. Ross
DDDiego H. Delgado
Diego H. Delgado